All Companies

4D Molecular Therapeutics
De­vel­op­ing the Di­rect­ed Ther­a­peu­tic Vec­tor Evo­lu­tion plat­form of nov­el AAV vec­tors to de­liv­er genes to any tis­sue or or­gan in the body. In con­trast to first-gen­er­a­tion vec­tors, 4D's cus­tomized... [more in­for­ma­tion]
Ablynx nv ABLX:BR
Nano­body plat­form with 8 com­pounds in its clin­i­cal pipe­line in ar­eas in­clud­ing aTTP, RA, SLE, RSV and I-O. Po­ten­tial for first pro­pri­e­tary prod­uct (ca­pla­cizumab) EU launch in 2018. Mul­ti­ple part­n­ers,... [more in­for­ma­tion]
Accera, Inc.
Ad­dress­ing the metabolic de­fect fun­da­men­tal to the patho­phy­si­ol­o­gy of Alzheimer's Dis­ease. Lead com­pound in­duces ke­to­sis, sup­p­ly­ing an al­ter­na­tive en­er­gy source for the pro­gres­sive de­c­line in... [more in­for­ma­tion]
AcelRx Pharmaceuticals, Inc. ACRX
De­vel­op­ing DSU­VIA (ARX-04) - HCP ad­min­is­tered sufen­tanil nan­otab with op­por­tu­ni­ty in ER de­part­ments, am­bu­la­to­ry surgery cen­ters, and paramedic tran­s­ports; met all end­points in 2 piv­o­tal Ph 3 studies,... [more in­for­ma­tion]
Achillion Pharmaceuticals, Inc. ACHN
Pipe­line of com­ple­ment fac­tor D in­hibi­tors to treat rare dis­eas­es such as PNH and C3G. ACH-4471 in Ph 2 trials, with da­ta ex­pect­ed 1H2017. Short-du­ra­tion, pan-geno­typ­ic, oral treat­ment for HCV with... [more in­for­ma­tion]
Adamas Pharmaceuticals, Inc. ADMS
Fo­cused on treat­ing time-de­pen­dent dis­ease symp­toms of CNS di­s­or­ders by de­vel­op­ing nov­el chrono-synchro­nous ther­a­peu­tic so­lu­tions as sin­gle agent drugs and fixed dose com­bi­na­tions. The Com­pany... [more in­for­ma­tion]
Adaptimmune Therapeutics PLC ADAP
Mul­ti­ple trials on­go­ing in both solid tu­mors and he­ma­to­log­ic can­cer types with pro­pri­e­tary T-cell en­gi­neer­ing plat­form. Da­ta read­out from NY-ESO SPEAR T-cells in NS­CLC and ovarian can­cer and da­ta from... [more in­for­ma­tion]
Affimed N.V. AFMD
En­gi­neer­ing NK cell and T-cell en­gag­ing bis­pe­cif­ic anti­bodies and Tris­pe­cif­ic Abs. Lead pro­gram AFM13(CD30/CD16A)in a Ph1b com­bo w/ Keytru­da for Hodgkins Lym­pho­ma. AFM13 - Ph2a monother­a­py for HL,... [more in­for­ma­tion]
Akari Therapeutics Plc AKTX
De­vel­op­ing cov­ersin, a se­cond-gen­er­a­tion com­ple­ment com­po­nent-C5 in­hibi­tor, to pre­vent re­lease of C5a and for­ma­tion MAC. Ph 2 da­ta in Parox­ys­mal noc­tur­nal he­mo­globin­uria (PNH) due in 1H17 as well as... [more in­for­ma­tion]
Amarin Corporation AMRN
Fo­cused on the de­vel­op­ment and com­mer­cial­iza­tion of ther­a­peu­tics to im­prove car­dio­vas­cu­lar health. Vas­ce­pa is the first and on­ly pure EPA ome­ga-3 fat­ty acid ap­proved to low­er trig­lyc­eride lev­els in... [more in­for­ma­tion]
AntibioTX Private
Clin­i­cal stage, fo­cused on the de­vel­op­ment of their Tx-class antibi­otics plat­form. The Tx-class antibi­otics plat­form us­es its new mech­anism of ac­tion to treat bac­te­rial in­fec­tions and re­lat­ed... [more in­for­ma­tion]
Apricus Biosciences, Inc. APRI
Apri­cus Bio­s­ciences, Inc. (APRI) is a bio­phar­ma­ceu­ti­cal com­pany ad­vanc­ing in­no­va­tive medicines in urol­o­gy and rheu­ma­tol­o­gy. Apri­cus has two prod­uct can­di­dates cur­rent­ly in de­vel­op­ment. Fo­cused on U.S. [more in­for­ma­tion]
Aquinox Pharmaceuticals, Inc. AQXP
Dis­cov­er­ing and de­vel­op­ing tar­get­ed ther­a­peu­tics in in­flam­ma­tion and im­muno-on­col­o­gy. Lead as­set, AQX-1125, is an oral, once dai­ly, small molecule ac­ti­va­tor of SHIP1. AQX-1125 is cur­rent­ly in Ph3 for... [more in­for­ma­tion]
A pri­vate, clin­i­cal-stage bio­phar­ma­ceu­ti­cal com­pany that has lev­er­aged its plat­form of benz­imi­da­zole deri­va­tives to de­vel­op a ro­bust drug pipe­line of oral­ly avai­l­able, po­tent, and se­lec­tive small... [more in­for­ma­tion]
Asklepion Pharmaceuticals
Pri­vate, fo­cused on the de­vel­op­ment of IV Cit­rul­line for rare pe­di­a­tric dis­eas­es. First in­di­ca­tion, the pre­ven­tion of sig­ni­f­i­cant se­que­lae of pe­di­a­tric acute car­diopul­mo­nary by­pass-in­duced lung... [more in­for­ma­tion]
Rev­enue gen­er­at­ing, ded­i­cat­ed to pe­ripher­al nerve re­pair with a port­fo­lio of re­gen­er­a­tive medicine prod­ucts avai­l­able in the US, Ca­na­da and sev­er­al other coun­tries. Prod­ucts in­clude Avance Nerve... [more in­for­ma­tion]
Bellicum Pharmaceuticals Inc. BLCM
De­vel­op­ing CAR T/TCR ther­a­pies with molec­u­lar switch tech­nol­o­gy and co-stim do­mains en­abling phar­ma­co­log­ic con­trol over cells for en­hanced safe­ty and ef­fi­ca­cy. Mul­ti­ple Ph 1/2 trials are un­der­way:... [more in­for­ma­tion]
Biohaven Pharmaceuticals, Inc BHVN
De­vel­op­ing a port­fo­lio of in­no­va­tive, late-stage prod­uct can­di­dates tar­get­ing neu­ro­log­i­cal dis­eas­es, in­clud­ing rare di­s­or­ders. Lead de­vel­op­ment pro­grams in­clude mul­ti­ple com­pounds across its CGRP... [more in­for­ma­tion]
BioPharmX BPMX
Der­ma­tol­o­gy-fo­cused, de­vel­op­ing BPX-01 for top­i­cal mino­cy­c­line acne and rosacea treat­ment, based on its nov­el hy­drophil­ic top­i­cal for­mu­la­tion tech­nol­o­gy. Re­port­ed Ph 2b da­ta with BPX-01 in acne. Phase... [more in­for­ma­tion]
Camurus AB CAMX:ST
De­vel­op­ing en­hanced prod­ucts by com­bin­ing pro­pri­e­tary Fluid­Crys­tal® for­mu­la­tion for sol­u­bi­l­iza­tion and sta­bi­l­iza­tion with ac­tive phar­ma­ceu­ti­cal sub­s­tances. Lead prod­uct CAM2038, for Opi­oid... [more in­for­ma­tion]
Catalyst Pharmaceuticals, Inc. CPRX
De­vel­op­ing Fir­dapse for the treat­ment of or­phan dis­ease in­di­ca­tion, Lam­bert-Ea­ton Myas­thenic Syn­drome (LEMS) with pos­i­tive Ph 3 da­ta and ad­di­tio­n­al Ph 3 trial re­sults ex­pect­ed in 2017. Al­so de­vel­op­ing... [more in­for­ma­tion]
Cellectis SA CLLS
Lead­er in en­gi­neered al­lo­gene­ic (off-the-shelf) CAR-T ther­a­peu­tics. Pipe­line in­cludes pro­pri­e­tary pro­grams and Pfiz­er and Servi­er part­n­er­ships on nu­mer­ous tar­gets in on­col­o­gy. Lead in­ter­nal pro­gram... [more in­for­ma­tion]
Chi-Med HCM
De­vel­op­ment pipe­line of eight nov­el late stage on­col­o­gy can­di­dates, with five Ph 3 trials un­der­way, fu­eled by its pro­f­itable Chi­nese com­mer­cial plat­form. Fruquin­tinib (VEG­FR in­hibi­tor, LLY-part­nered)... [more in­for­ma­tion]
A com­mer­cial stage, pre­ci­sion gene edit­ing com­pany. Cibus' tech­nol­o­gy has ap­pli­ca­tions in non-GMO crop de­vel­op­ment, in­dus­trial biotech and hu­man health. The com­pany uti­l­izes Gene Re­pair... [more in­for­ma­tion]
CytomX Therapeutics, Inc. CTMX
Anti­body pro­drug (pro­body) plat­form se­lec­tive­ly en­hances anti­body bind­ing within the tu­mor mi­croen­vi­ron­ment, en­abling treat­ments de­signed to en­hance tu­mor tar­get­ing and wi­den the ther­a­peu­tic win­dow. [more in­for­ma­tion]
Enzo Biochem, Inc. ENZ
De­vel­op re­search tools, di­ag­nos­tics and ther­a­peu­tics and pro­vides ref­er­ence lab­o­ra­to­ry ser­vices to the med­i­cal com­mu­ni­ty. Ac­tiv­i­ties in­clude R&D, man­u­fac­tur­ing and mar­ket­ing of biomed­i­cal re­search... [more in­for­ma­tion]
Epigenomics AG EPGNY
Molec­u­lar di­ag­nos­tics com­pany fo­cused on non-in­va­sive screen­ing tests for on­col­o­gy. Lead prod­uct, Epi pro­Colon, is a blood based test to screen for colon can­cer. Reached 99.5% com­pliance rate to CRC... [more in­for­ma­tion]
Evotec AG EVT-DE
EVT In­no­vate is an in­ter­nal drug dis­cov­ery plat­form with over 70 prod­uct op­por­tu­ni­ties and ex­per­tise across dis­eas­es ar­eas. In­no­vate is pro­gress­ing nov­el, first-in-class, pre-clin­i­cal as­sets to... [more in­for­ma­tion]
Flex Pharma, Inc. FLKS
There is cur­rent­ly no proven or ef­fec­tive prod­uct for mus­cle cramps and spasms. Most mus­cle cramps are not caused by de­hy­dra­tion, lac­tic acid, elec­tro­lyte im­bal­ance, or mus­cle tight­ness. That is why... [more in­for­ma­tion]
Forward Pharma A/S FWP
Since 2005 For­ward Phar­ma has been de­vel­op­ing FP187, a pro­pri­e­tary for­mu­la­tion of DMF (dimethyl fu­marate) for the treat­ment of in­flam­ma­to­ry and neu­ro­log­i­cal in­di­ca­tions. The Com­pany owns a IP... [more in­for­ma­tion]
Lead pro­gram Ela­fi­branor (GFT505) in Phase 3 trials for NASH. Ela­fi­branor is a PPAR al­pha/del­ta ag­on­ist cur­rent­ly in a Ph 3 trial with com­ple­tion of en­roll­ment for in­ter­im look ex­pect­ed 1Q18. On­go­ing... [more in­for­ma­tion]
GenSight Biologics SIGHT.PA
Gene ther­a­pies for se­vere reti­nal and CNS de­gen­er­a­tive patholo­gies. Lead prod­uct, GS010, is in Ph3 for the treat­ment of Le­ber Hered­i­tary Op­tic Neu­ro­pa­thy (LHON) with da­ta ex­pect­ed in 2018. Pipe­line... [more in­for­ma­tion]
De­vel­op­ing im­muno-on­col­o­gy prod­ucts for the treat­ment of vari­ous can­cer types us­ing its Gly­co­Ex­press™ (GEX™) and Gly­co­Body™ (GET™) tech­nolo­gies. Has clin­i­cal pipe­line of four... [more in­for­ma­tion]
Inspirion Delivery Sciences LLC
Pri­vate­ly held spec. phar­ma co ded­i­cat­ed to ad­vanc­ing so­lu­tions in the field of pre­scrip­tion drug abuse de­ter­rence. U.S. Rights for Mor­phaBond ER™ and Rox­y­Bond™ li­censed to Daiichi Sankyo,... [more in­for­ma­tion]
Loxo Oncology, Inc. LOXO
De­vel­ops tar­get­ed drugs for the treat­ment of can­cer in ge­net­i­cal­ly defined pa­tient pop­u­la­tions. Lead pro­gram: pur­pose built pan TRK in­hibi­tor in a Ph 2 solid tu­mor study with FDA break­through... [more in­for­ma­tion]
Medigene AG MDGEF
Im­muno-on­col­o­gy com­pany fo­cused on per­so­n­al­ized T cell-based ther­a­pies. MDG1011, TCR tar­get­ing PRAME anti­gen, to en­ter clin­ic in 2H17 for bas­ket of he­ma­to­log­i­cal in­di­ca­tions (AML, MDS and MM). [more in­for­ma­tion]
Pro­f­itable clin­i­cal stage plat­form tech­nol­o­gy drug de­liv­ery com­pany fo­cused on long-act­ing in­jectable for­mu­la­tions for sub­cu­ta­neous de­liv­ery in­jec­tion to pro­vide sys­temic ef­fect while min­i­miz­ing... [more in­for­ma­tion]
Medivir AB MVIR-B.SE
Shift in strat­e­gy and pipe­line in ac­qui­si­tion of two late stage on­col­o­gy pro­grams. New CEO, Chris­tine Lind ap­point­ed in April 2017. De­vel­op­ing MIV-711: a cathepsin K in­hibi­tor in cur­rent Ph 2a study... [more in­for­ma­tion]
MorphoSys AG MPSYF
Clin­i­cal stage anti­body co. with dense pipe­line of >100 prod­ucts in mul­ti­ple stages/in­di­ca­tions. First part­n­er prod­uct on mar­ket (JNJ; Trem­fya for mod­er­ate to se­vere pso­ri­a­sis). Pro­pri­e­tary pro­gram... [more in­for­ma­tion]
Motif Bio plc MTFB
Ph 3 antibi­ot­ic com­pany fo­cused on life-threat­en­ing in­fec­tions caused by mul­ti-drug re­sis­tant bac­te­ria. Lead can­di­date, Iclaprim, be­ing de­vel­oped for treat­ment of acute bac­te­rial skin and skin... [more in­for­ma­tion]
Nanobiotix SA NANO.PA
De­vel­op­ing first in class nano­par­ti­cle-based ra­dio-en­hancer NBTXR3 for soft tis­sue sar­co­ma, head and neck, liv­er, pros­tate, rec­tal and other can­cers. Al­so be­ing de­vel­oped for in si­tu vac­ci­na­tion in... [more in­for­ma­tion]
Nordic Nanovector ASA NANO.OL
Fo­cused on de­vel­op­ment of Anti­body-Ra­dionu­clide-Con­ju­gates (ARC). The lead as­set Be­ta­lutin, a ra­dioim­munother­a­peu­tic for the treat­ment of Non-Hodgkin Lym­pho­ma, en­ter­ing piv­o­tal Ph 2 trial 2H17. [more in­for­ma­tion]
Novus Therapeutics NVUS
Novus Ther­a­peu­tics is a phar­ma­ceu­ti­cal com­pany fo­cus­ing on the ac­qui­si­tion, de­vel­op­ment, and com­mer­cial­iza­tion of ear, nose, and throat (ENT) prod­ucts. The com­pany has two tech­nolo­gies, each of which... [more in­for­ma­tion]
OncoMed Pharmaceuticals OMED
a clin­i­cal-stage com­pany dis­cov­er­ing and de­vel­op­ing nov­el an­ti-can­cer ther­a­peu­tics. On­coMed is ad­vanc­ing its im­muno-on­col­o­gy R&D pipe­line, in­clud­ing an­ti-TIG­IT, whol­ly-owned GITRL-Fc trimer, and... [more in­for­ma­tion]
Oncopeptides AB ONCO:ST
De­vel­op­ing Yga­lo (melflufen), a pep­ti­dase po­ten­ti­at­ed alky­la­tor which con­cen­trates cy­to­tox­ic ac­tiv­i­ty for late-stage re­lapsed re­frac­to­ry mul­ti­ple myelo­ma, an in­di­ca­tion with limit­ed treat­ment op­tions. [more in­for­ma­tion]
Oryzon Genomics ORY:MA
De­vel­ops per­so­n­al­ized ther­a­peu­tics for pa­tients with can­cers or neu­rode­gen­er­a­tive di­s­or­ders. The com­pany’s lead com­pound, ORY-1001, is a high­ly po­tent LS­D1 in­hibi­tor cur­rent­ly in Ph 1/2a... [more in­for­ma­tion]
Fo­cused on anes­th­e­sia around game chang­ing as­set Remi­ma­zo­lam, a short-act­ing anes­thet­ic. Remi­ma­zo­lam com­plet­ed a pos­i­tive Ph 3 in pro­ce­du­ral se­da­tion in the US. Pos­i­tive safe­ty da­ta in ASA III/IV... [more in­for­ma­tion]
Pharma Mar SA PHM.MC
On­col­o­gy-fo­cused com­pany with 1H17 to­tal rev­enues of &eu­ro;96.9M. Yon­delis, for soft tis­sue sar­co­ma and ovarian can­cer, is com­mer­cial­ized in 75+ coun­tries, di­rect sales-force in Eu­rope, part­n­er­ship in... [more in­for­ma­tion]
Pharming Group NV PHARM.AS
GMP-com­pliant, vali­dat­ed plat­form that pro­duces high qual­i­ty re­com­bi­nant hu­man pro­tein more eco­nom­i­cal­ly than all other cur­rent tech­nolo­gies. Lead Ru­con­est is an rhC1-es­terase in­hibi­tor ap­proved to... [more in­for­ma­tion]
PhaseBio Pharmaceuticals, Inc.
Clin­i­cal-stage, de­vel­op­ing new and im­proved bio­ther­a­peu­tics for the treat­ment of or­phan dis­eas­es, with an ini­tial fo­cus on car­diopul­mo­nary di­s­or­ders. Pro­pri­e­tary tech­nol­o­gy plat­form us­es re­com­bi­nant... [more in­for­ma­tion]
Photocure ASA PHCUF
Urol­o­gy-fo­cused spec-phar­ma. Hexvix®/Cysview® with pro­pri­e­tary pho­to­dy­nam­ic tech­nol­o­gy is on mar­ket for the di­ag­no­sis and ma­n­age­ment of blad­der can­cer. Com­mer­cial­ized us­ing Co’s... [more in­for­ma­tion]
Pieris Pharmaceuticals, Inc. PIRS
De­vel­op­ing an­ti­calins (re­com­bi­nant pro­teins dif­fer­en­ti­at­ed from MAbs) for can­cer, se­vere asth­ma and ane­mia. PRS-080, lead hep­cidin an­ta­g­on­ist for ane­mia to en­roll mul­ti-dose Phase 2a pa­tients in 2017. [more in­for­ma­tion]
De­vel­op­ing safer and more ef­fec­tive ther­a­pies for metabolic dis­eas­es. Imeglimin (a mi­to­chon­dria-based MOA) for Type 2 di­a­betes is Ph 3 ready in the US and EU, pre­vi­ous­ly meet­ing glycemic end­points in... [more in­for­ma­tion]
Prima BioMed PBMD
Aus­tralian-based, mar­ket lead­er de­vel­op­ing LAG-3 in im­muno-on­col­o­gy. CMO/CSO Fr&ea­cute;d&ea­cute;ric Trie­bel dis­cov­ered the LAG-3 gene in 1990 and iden­ti­fied the func­tions and med­i­cal ap­pli­ca­tions of... [more in­for­ma­tion]
Probiodrug AG PB9.f
De­vel­op­ing prod­ucts for treat­ment of Alzheimer’s Dis­ease (AD). An­nounced pos­i­tive da­ta in June 2017 from the Ph 2a (SAPHIR) clin­i­cal trial for PQ912, a first in class small molecule QC... [more in­for­ma­tion]
Profusa, Inc.
CE Mark ap­proved med­i­cal sen­sor/health da­ta co. with clin­i­cal grade, wear­able, plat­form tech­nol­o­gy with a long-last­ing embedd­ed biosen­sor that out­lasts clos­est com­peti­tor by 2x and trans­mits re­al... [more in­for­ma­tion]
ProQR Therapeutics NV PRQR
Trans­for­ma­tive RNA medicines for the treat­ment of se­vere or­phan dis­eas­es such as CF and LCA Type 10, based on pro­pri­e­tary RNA re­pair plat­form tech­nolo­gies. Pro­QR's lead clin­i­cal pro­gram, QR-010,... [more in­for­ma­tion]
Protagonist Therapeutics PTGX
Clin­i­cal-stage, plat­form tech­nol­o­gy based on dis­cov­ery and de­vel­op­ment of pep­tide-based NCEs. Lead can­di­date is for in­flam­ma­to­ry bow­el dis­ease (ul­cer­a­tive coli­tis and Crohn's dis­ease), a... [more in­for­ma­tion]
Protalix BioTherapeutics PLX
De­vel­op­ing “bio­bet­ters” us­ing pro­pri­e­tary plant cell tech­nol­o­gy. Ap­proved Elely­so vali­dat­ed the plat­form. Pro­tal­ix’s de­vel­op­ment pipe­line in­cludes: PRX-102, a mod­i­fied ver­sion of the... [more in­for­ma­tion]
Pulse Biosciences, Inc. PLSE
A de­vel­op­ment-stage med­i­cal de­vice com­pany us­ing a nov­el and pro­pri­e­tary plat­form tech­nol­o­gy called Nano-Pulse Elec­tro-Sig­nal­ing or NPES. NPES is a lo­cal and drug-free tech­nol­o­gy that uti­l­izes... [more in­for­ma­tion]
RedHill Biopharma RDHL
Fo­cused on the de­vel­op­ment and com­mer­cial­iza­tion of small molecule drugs for the treat­ment of in­flam­ma­to­ry and gas­troin­testi­nal dis­eas­es, in­clud­ing can­cer. Three com­pounds in Ph3 de­vel­op­ment, RHB-105... [more in­for­ma­tion]
ReNeuron Group plc RNUGF
Clin­i­cal-stage, UK-based cell ther­a­py com­pany with dif­fer­en­ti­at­ed al­lo­gene­ic off-the-shelf can­di­dates: chron­ic stroke dis­a­bil­i­ty (Ph3 ready, ini­ti­a­tion 2H 2017); crit­i­cal limb is­chemia (CLI);... [more in­for­ma­tion]
Repros Therapeutics Inc. RPRX
De­vel­op­ing Proellex, an oral de­liv­er­able, in Ph 2b to treat uterine fi­broids and en­dometrio­sis - ex­pect­ing to com­plete Ph 2b in Q2 2017; Re­pros al­so de­vel­op­ing An­drox­al in Ph3 to treat se­condary... [more in­for­ma­tion]
Rigel Pharmaceuticals RIGL
In April 2017, Rigel sub­mitt­ed a NDA for its lead prod­uct can­di­date, Ta­valisse (fos­ta­ma­tinib di­s­odi­um), for the treat­ment of chron­ic and per­sis­tent im­mune throm­bo­cy­tope­nia (ITP). The FDA pre­vi­ous­ly... [more in­for­ma­tion]
Savara Inc. SVRA
De­vel­ops in­ha­la­tion ther­a­pies for the treat­ment of pa­tients with rare pul­mo­nary con­di­tions. Three pipe­line prod­ucts: Mol­gradex, an in­haled ne­b­u­l­ized GM-CSF to treat Pul­mo­nary Alve­o­lar Pro­tei­no­sis... [more in­for­ma­tion]
Stemline Therapeutics, Inc. STML
Three On­col­o­gy Prod­ucts in the Clin­ic. SL-401, a tar­get­ed CD123 in Ph 2 open-la­bel reg­is­tra­tion trial for BPD­CN. Ad­di­tio­n­al Ph 2 trials are en­rolling for other CD123+ in­di­ca­tions in­clud­ing AML in CR,... [more in­for­ma­tion]
Mar­ket lead­er in au­to­ma­tion sys­tems and soft­ware for the di­ag­nos­tics in­dus­try. In­s­talled base of >13,000 sys­tems across 20 fam­i­lies in­clud­ing PAN­THER (Ho­log­ic), Li­a­son XL (Di­a­Sorin), VI­DAS... [more in­for­ma­tion]
Strongbridge Biopharma SBBP
Strong­bridge is a com­mer­cial-stage com­pany fo­cused on ther­a­pies for rare dis­eas­es. Launched KEVEYIS for pe­ri­od­ic par­tial paral­y­sis in April 2017 in the US. Lead clin­i­cal as­set RE­COR­LEV is in Phase 3... [more in­for­ma­tion]
Sutro Biopharma
Fo­cused on de­vel­op­ing next gen­er­a­tion anti­body drug con­ju­gates (ADCs) and mul­ti-spe­cif­ic anti­body-based ther­a­peu­tics for can­cer ther­a­py. The com­pany’s dis­cov­ery and de­vel­op­ment ef­forts are... [more in­for­ma­tion]
Symic Bio
De­vel­op­ing a new ther­a­peu­tic cat­e­go­ry of bio­con­ju­gates that di­rect­ly tar­get the ex­tra­cel­lu­lar ma­trix (ECM). Two clin­i­cal Phase 1/2a can­di­dates which in­clude crit­i­cal limb is­chemia (SB-030) and dis­ease... [more in­for­ma­tion]
Targovax TRVX:OS
De­vel­op­ing two com­ple­men­tary ap­proach­es; a pep­tide-based im­munother­a­py plat­form for pa­tients with RAS-mu­tat­ed can­cers and a virus-based im­munother­a­py plat­form based on en­gi­neered on­co­lyt­ic virus­es... [more in­for­ma­tion]
TCR2 Therapeutics ("TCR squared")
Pro­pri­e­tary TRuC™ plat­form based on T cell re­cep­tor fu­sion con­structs that em­ploy the full sig­nal­ing pow­er of the T cell re­cep­tor (TCR). This cell ther­a­py ap­proach al­lows per­sis­tent killing of... [more in­for­ma­tion]
Tessa Therapeutics
Clin­i­cal stage bio­phar­ma­ceu­ti­cal com­pany fo­cused on the treat­ment of can­cer by redi­rect­ing the body’s po­tent an­ti-vi­ral im­mune re­sponse to rec­og­nize and kill can­cer cells. Tes­sa’s core... [more in­for­ma­tion]
TiGenix NV TIG
Ti­Genix NV is de­vel­op­ing ther­a­pies for se­ri­ous med­i­cal con­di­tions by ex­ploit­ing the an­ti-in­flam­ma­to­ry prop­er­ties of al­lo­gene­ic, or donor-de­rived, stem cells. Lead prod­uct, Cx601 for the treat­ment of... [more in­for­ma­tion]
Tocagen Inc. TOCA
Can­cer-se­lec­tive gene ther­a­py com­pany. Lead pro­gram To­ca 511 and To­ca FC are be­ing studied in a reg­is­tra­tio­n­al Ph 2/3 trial for re­cur­rent high grade glio­ma (rHGG). A Ph 1 study of To­ca 511 and To­ca FC... [more in­for­ma­tion]
Vericel Corporation VCEL
Cam­bridge-based, mar­kets three au­tol­o­gous cell ther­a­py prod­ucts in the US. In 1Q 2017, com­menced MA­CI launch ac­tiv­i­ties and an­nounced treat­ment of the first pa­tient on Fe­bruary 1. An­nounced FDA Fast... [more in­for­ma­tion]
Veru Healthcare veru
De­vel­op­ing and com­mer­cial­iz­ing phar­ma­ceu­ti­cals and de­vices in urol­o­gy and on­col­o­gy. Uti­l­izes the 505(b)2 path­way for more eco­nom­i­cal and fast-track ap­pro­val pro­cess­es. Prod­uct can­di­dates are for BPH,... [more in­for­ma­tion]
vTv Therapeutics, Inc. VTVT
Late-stage, next Ph. 3 Alzheimer's da­ta read-out af­ter AX­ON. Azeli­ra­gon - oral, small-molecule in­hibi­tor of the Re­cep­tor for Ad­vanced Gly­ca­tion End­prod­ucts (RAGE), lies up­stream to AD patholo­gies... [more in­for­ma­tion]
Wilson Therapeutics WTX:ST
De­vel­op­ing nov­el ther­a­pies for pa­tients with rare dis­eas­es, with plans to start a piv­o­tal Ph 3 trial this year with WTX101, a first in class agent for Wil­son Dis­ease - a ge­net­ic con­di­tion re­sult­ing in... [more in­for­ma­tion]